MedTrace Logo

The Effect of Anakinra on Insulin Secretion

NCT01285232 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-03-26

No results posted yet for this study

Summary

Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the progressive β-cell dysfunction in type 2 diabetes mellitus.

Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.

Conditions

  • Glucose Intolerance
  • Impaired Insulin Secretion
  • Diabetes Mellitus Type 2

Interventions

DRUG

Anakinra

150 mg sc once daily during four weeks

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • C.J. Tack, MD, PhD, Prof. of Diabetology · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-03-31
Completion
2012-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285232 on ClinicalTrials.gov